Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Phenylpiperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.71 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.71 |
| ▸ | HTR3B | O95264 | 3/20 | 0.71 |
| ▸ | HTR3A | P46098 | 3/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylpiperazine SCHEMBL8141187 | 1.00 | SIGMAR1 (0.71) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL3866050 | 1.00 | SIGMAR1 (0.71) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL8141189 | 1.00 | SIGMAR1 (0.71) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL11621472 | 0.89 | ADRB1 (0.83) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL2002893 | 0.85 | ADRB1 (0.77) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL24889 | 0.84 | ADRB1 (1.00) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL29135595 | 0.84 | ADRB1 (1.00) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL27858598 | 0.84 | ADRB1 (1.00) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Phenylpiperazine SCHEMBL55125 | 0.84 | ADRB1 (1.00) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Fumaric Acid SCHEMBL27454231 | 0.83 | CHRNB2 (0.67) | SIGMAR1ADRB1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7459557-B2 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-02 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007005214-A1 | SUBSTITUTED {4(4-PHENYL-PIPERAZIN-1YL)-CYCLOHEXYL}-UREA COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007001818-A2 | SUBSTITUTED ISOINDOLE-1,3-DIONES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | ADRA1D, ADRA1A, ADRB1 | ADRB1 3/4885HTR2C 187/4885HTR2A 158/4885 |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | ADRA1D, ADRA1A, ADRB1 | ADRB1 3/4885HTR2C 64/4885HTR2A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.